Artificial intelligence has inspired computer-aided drug discovery. The widespread adoption of machine learning, in multiple scientific disciplines, advances the computing hardware & software tools to continuously fuel the development of AI in drug discovery. Further, the initial uncertainties regarding applications of AI in pharmaceutical discovery have disappeared and subsequently benefitting medicinal chemistry. For instance, in 2018, the FDA has approved 59 new drugs with the help of AI which was 20% more than in 2017 and 2016. And was the highest number since 1996. The approvals included 19 first-in-class agents, 34 novel drugs for rare diseases, and a record seven biosimilars. The use of big data and AI is immensely accelerating the identification of more precise drugs.
Also, Artificial intelligence has been an effective contributor to drug development during the Covid-19 pandemic. AI was used to identify and replicate protein structure. It supported the drug development market in accelerating drug discovery through validation and virtual screening. For instance, in 2019, during the pandemic, researchers from TCS Innovation Lab had announced their drug discovery process using AI. As the traditional development processes are time-consuming and involve a huge cost. AI and its subsets like machine learning make it easier to design a drug with saving a lot of time. This is increasing the use of AI in drug discovery by the pharmaceutical industries, and it will upsurge the market in the forecasted period.
Also Read: http://www.marketwatch.com/story/artificial-intelligence-in-drug-di...
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for the diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.”
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.”
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.”
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.”
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.”
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.”
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.
Telemedicine is the delivery of health care services, where
distance is a critical factor, by all health care professionals
using information and communications technologies for
the exchange of valid information for diagnosis, treatment
and prevention of disease and injuries, research and
evaluation, and for the continuing education of health
care providers, all in the interests of advancing the health
of individuals and their communities.
Telemedicine can be determined as an integration
of several components including information and
communication technologies, hardware and soware
technologies and medical services operating together in
order to provide required features or services to users
Telemedicine can be determined as an integration
of several components including information and
communication technologies, hardware and soware
technologies and medical services operating together in
order to provide required features or services to users
Telemedicine can be determined as an integration
of several components including information and
communication technologies, hardware and soware
technologies and medical services operating together in
order to provide required features or services to users
as shown in Fig 1. e underlying technologies are seen
as a black box to the users and they are responsible for
facilitating processes of each proposed service
Also Read: http://www.marketwatch.com/story/alpha-olefin-sulfonate-aos-market-...
.......... .......... ........... .......... ........... .......... ........... .......... ........... .......... ........... .......... ........... ...........
....................................... ................................
EDUCATION AND PRACTICE Fundamentals
" Introduction to the practice of telemedicine
John Craig* and Victor Patterson*
w

Department of Neurology, Royal Victoria Hospital, Belfast, UK;
w
Centre for Online Health, University of Queensland, Brisbane,
Australia
Summary
Telemedicine is the delivery of health care and the exchange of health-care information across distances. It is not
a technology or a separate or new branch of medicine. Telemedicine episodes may be classified on the basis of:
(1) the interaction between the client and the expert (i.e. realtime or prerecorded), and (2) the type of
information being transmitted (e.g. text, audio, video). Much of the telemedicine which is now practised is
performed in industrialized countries, such as the USA, but there is increasing interest in the use of telemedicine
in developing countries. There are basically two conditions under which telemedicine should be considered:
(1) when there is no alternative (e.g. in emergencies in remote environments), and (2) when it is better than
existing conventional services (e.g. teleradiology for rural hospitals). For example, telemedicine can be expected
to improve equity of access to health care, the quality of that care, and the efficiency by which it is delivered.
Research in telemedicine increased steadily in the late 1990s, although the quality of the research could be
improved – there have been few randomized controlled trials to date.
Introduction
One of the great challenges facing humankind in the
21st century is to make high-quality health care available
to all. Such a vision has been expressed by the World
Health Organization (WHO) in its health-for-all strategy
in the 21st century.
1
Realizing this vision will be difficult,
perhaps impossible, because of the burdens imposed on
a growing world population by old and new diseases,
rising expectations for health, and socioeconomic
conditions that have, if anything, increased disparities in
health status between and within countries.
Traditionally, part of the difficulty in achieving
equitable access to health care has been that the
provider and the recipient must be present in the same
place and at the same time. Recent advances in
information and communication technologies,
however, have created unprecedented opportunities for
overcoming this by increasing the number of ways that
health care can be delivered. This applies both to
developing countries with weak or unstable economies
and to industrialized countries. The possibilities for
using information and communication technologies to
improve health-care delivery (‘health telematics’) are
increasingly being recognized. The WHO has stated that
with regard to its health-for-all strategy it recommends
that the WHO and its member states should:
integrate the appropriate use of health telematics in
the overall policy and strategy for the attainment of
health for all in the 21st century, thus fulfilling the
vision of a world in which the benefits of science,
technology and public health development are made
equitably available to all people everywhere.
2
Such a commitment to improve health-care delivery,
by utilizing information and telecommunications
technologies, is also being considered by those with the
financial means to do so, for example, the participants
in various European Commission projects. At the
national and subnational level, there is also evidence of
governmental interest in the benefits that these
technologies might bring to health care. For example,
in the UK, information technology including
telemedicine is at the heart of the government’s
strategy to modernize and improve the NHS.
3
Telemedicine, the area where medicine and infor-
mation and telecommunications technology meet, is
probably the part of this revolution that could have the
greatest impact on healthcare deliBased on service, the market is fragmented into Tele-consulting, Tele-monitoring, and Tele-education. The Tele-consulting segment generated more than 45% revenue in 2020. The market is expected to grow at a significant rate during the forecast period. As it permits patients to have appointments with experts at any instance of time, without any waiting period.
Based on Technology, the market is bifurcated into Machine Learning and Other technologies. The Machine Learning segment dominated the market in 2020 as the advances in wireless technology, miniaturization, and computational power with the use of machine learning architectures are fueling the development of more refined and powerful AI tools.
Based on Components, the market is bifurcated into Software and Service. The Software segment accounted for the major revenue portion in 2020. As the Companies which use software has low cost and takes less time to market the drug with low failure rates.
Based on Drug Type, the market is bifurcated into Small molecules and Large molecules. The Small molecule segment accounted for the major revenue portion in 2020. The sector is anticipated to observe significant growth in the upcoming years as their small size makes them easily ingestible in the gastrointestinal tract where active substances are immediately absorbed into the bloodstream and can travel anywhere in the body.
Based on Application, the market is bifurcated into Drug optimization and repurposing, Preclinical testing, and others. The Drug optimization and repurposing segment accounted for the major revenue portion in 2020. As the AI platforms help in identifying alternative applications for existing medicines which can help pharma companies expand their collection of offerings and assist in producing alternative therapies through repurposing in pharmaceutical products.
Based on Therapeutic Area, the market is bifurcated into Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurogenerative Diseases, Oncology, and Others. The Oncology segment accounted for the major revenue portion in 2020. As, as AI plays an important role in the early identification of cancer. Moreover, cancer treatments may be different for every patient and personalized medicine has proven to be an actual alternative.
Based on End-user, the market is bifurcated into Contract Research Organizations, Pharmaceutical & Biotechnology Companies, and Research Centers, and Academic & Government Institutes. The Pharmaceutical & Biotechnology Companies segment is anticipated to observe lucrative growth. As they are more prone to work in integration with bioinformatics, computational engineering, nanotechnology, and pharmacogenomics methods into the drug discovery process which will lead to the next stage of advances in drug discovery.
For a better understanding of the market adoption of the Artificial Intelligence in Drug Discovery, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the Artificial Intelligence in Drug Discovery industry and generated the maximum revenue in 2020 owing to the presence of key companies and healthcare infrastructure with the highest spending’s in the world. However, the Europe region would also grow at the same pace during the forecast period.
Some of the major players operating in the market include IBM Corporation, Microsoft, Google, NVIDIA Corporation, Atomwise, Inc., Insilico Medicine, BIOAGE, BenevolentAI, Numerate, NuMedii, etc. Several M&As along with partnerships have been undertaken by these players to develop the Artificial Intelligence in Drug Discovery market.
Also Read: http://www.marketwatch.com/story/medical-wet-electrodes-market-rese...
List OF CONTENTS AND TABLES:
1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Global Artificial Intelligence in Drug Discovery Market Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Global Artificial Intelligence in Drug Discovery Market
2.1.1 Main Objective of the Global Artificial Intelligence in Drug Discovery Market
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 TOP START-UPS UNDER ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY SECTOR
6 GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY AMID COVID-19
7 GLOBAL ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET REVENUE (USD MN), 2019-2027F
8 MARKET INSIGHTS BY TECHNOLOGY
8.1 Machine Learning
8.1.1 Deep Learning
8.1.2 Supervised Learning
8.1.3 Reinforcement Learning
8.1.4 Unsupervised Learning
8.1.5 Other Machine Learning Technologies
8.2 Other Technologies
9 MARKET INSIGHTS BY COMPONENT
9.1 Software
9.2 Service
10 MARKET INSIGHTS BY DRUG TYPE
10.1 Small Molecule
10.2 Large Molecule
11 MARKET INSIGHTS BY APPLICATION
11.1 Drug Optimization and Repurposing
11.2 Preclinical Testing
11.3 Others
12 MARKET INSIGHTS BY THERAPEUTIC AREA
12.1 Cardiovascular Disease
12.2 Infectious Disease
12.3 Metabolic Diseases
12.4 Neurodegenerative Diseases
12.5 Oncology
12.6 Others
13 MARKET INSIGHTS BY END-USER
13.1 Contract Research Organizations
13.2 Pharmaceutical & Biotechnology Companies
13.3 Research Centers and Academic & Government Institutes
14 MARKET INSIGHTS BY REGION
14.1 North America Artificial Intelligence in Drug Discovery Market
14.1.1 United States
14.1.2 Canada
14.1.3 Rest of North America
14.2 Europe Artificial Intelligence in Drug Discovery Market
14.2.1 Germany
14.2.2 France
14.2.3 United Kingdom
14.2.4 Italy
14.2.5 Spain
14.2.6 Rest of Europe
14.3 Asia Pacific Artificial Intelligence in Drug Discovery Market
14.3.1 China
14.3.2 Japan
14.3.3 India
14.3.4 Australia
14.3.5 Rest of Asia Pacific
14.4 Rest of World Artificial Intelligence in Drug Discovery Market
15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET DYNAMICS
15.1 Market Drivers
15.2 Market Challenges
15.3 Impact Analysis
16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OPPORTUNITIES
17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET TRENDS
18 LEGAL & REGULATORY FRAMEWORK
19 DEMAND AND SUPPLY SIDE ANALYSIS
19.1 Demand Side Analysis
19.2 Supply Side Analysis
19.2.1 Top Product Launches
19.2.2 Top Business Partnerships
19.2.3 Top Business Expansions, Investments and Divestitures
19.2.4 Top Merger and Acquisitions
20 VALUE CHAIN ANALYSIS
21 COMPETITIVE SCENARIO
21.1 Porter’s Five Forces Analysis
21.1.1 Bargaining power of Supplier
21.1.2 Bargaining power of Buyer
21.1.3 Industry Rivalry
21.1.4 Availability of Substitute
21.1.5 Threat of new Entrants
21.2 Competitive Landscape
21.2.1 Company Shares, By Revenue
22 COMPANY PROFILED
22.1 IBM Corporation
22.2 Microsoft
22.3 Google
22.4 NVIDIA Corporation
22.5 Atomwise, Inc.
22.6 Insilico Medicine
22.7 BIOAGE
22.8 BenevolentAI
22.9 Numerate
22.10 NuMedii
23 DISCLAIMER ----….….continued

CONTACT DETAILS :
[email protected]
+44 203 500 2763
+1 62 825 80070
971 0503084105